These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 18537758)
1. New approaches in the diagnosis of atherosclerosis and treatment of cardiovascular disease. Viljoen A Recent Pat Cardiovasc Drug Discov; 2008 Jun; 3(2):84-91. PubMed ID: 18537758 [TBL] [Abstract][Full Text] [Related]
2. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk. Shapiro MD; Fazio S Circ Res; 2016 Feb; 118(4):732-49. PubMed ID: 26892970 [TBL] [Abstract][Full Text] [Related]
3. Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis. Bertrand MJ; Tardif JC Expert Opin Emerg Drugs; 2017 Mar; 22(1):1-26. PubMed ID: 27927063 [TBL] [Abstract][Full Text] [Related]
4. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ; Watson KE; Talbert RL J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [TBL] [Abstract][Full Text] [Related]
5. Optimal management of combined dyslipidemia: what have we behind statins monotherapy? Tenenbaum A; Fisman EZ; Motro M; Adler Y Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960 [TBL] [Abstract][Full Text] [Related]
6. [Diabetic dyslipidaemia and the atherosclerosis]. Márk L; Dani G Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274 [TBL] [Abstract][Full Text] [Related]
8. Jeremiah Metzger Lecture: cholesterol, inflammation and atherosclerotic cardiovascular disease: is it all LDL? Gotto AM Trans Am Clin Climatol Assoc; 2011; 122():256-89. PubMed ID: 21686232 [TBL] [Abstract][Full Text] [Related]
10. Practical recommendations for the management of cardiovascular risk associated with atherogenic dyslipidemia, with special attention to residual risk. Spanish adaptation of a European Consensus of Experts. Grupo de trabajo de Dislipemia Aterogénica de la Sociedad Española de Arteriosclerosis y Grupo Europeo de Expertos Clin Investig Arterioscler; 2017; 29(4):168-177. PubMed ID: 28433209 [TBL] [Abstract][Full Text] [Related]
11. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia. Jacobson TA Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969 [TBL] [Abstract][Full Text] [Related]
12. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Nesto RW Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526 [TBL] [Abstract][Full Text] [Related]
13. 2017 Taiwan lipid guidelines for high risk patients. Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI; J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176 [TBL] [Abstract][Full Text] [Related]
14. [Place of fibrates for the treatment of patients with atherogenic dyslipidemia]. Ducobu J; Scheen AJ; Legat P; De Backer G; Van Gaal L; Velkeniers B; Kartounian J; Maes M; Hermans M Rev Med Liege; 2009 Oct; 64(10):512-8. PubMed ID: 19911665 [TBL] [Abstract][Full Text] [Related]
15. Lipid-lowering agents for nephrotic syndrome. Kong X; Yuan H; Fan J; Li Z; Wu T; Jiang L Cochrane Database Syst Rev; 2013 Dec; (12):CD005425. PubMed ID: 24327265 [TBL] [Abstract][Full Text] [Related]
16. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Reiner Z Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901 [TBL] [Abstract][Full Text] [Related]